{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:33:16Z","timestamp":1792459996070,"version":"4.5.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,1,31]],"date-time":"2014-01-31T00:00:00Z","timestamp":1391126400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s12185-014-1522-1","type":"journal-article","created":{"date-parts":[[2014,1,30]],"date-time":"2014-01-30T05:24:42Z","timestamp":1391059482000},"page":"219-226","source":"Crossref","is-referenced-by-count":25,"title":["Molecular genetics of peripheral T-cell lymphomas"],"prefix":"10.1007","volume":"99","author":[{"given":"Pier Paolo","family":"Piccaluga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Tabanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano A.","family":"Pileri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,31]]},"reference":[{"key":"1522_CR1","first-page":"158","volume-title":"WHO classification of tumors of hematopoietic and lymphoid tissues","author":"ES Jaffe","year":"2008","unstructured":"Jaffe ES, Harris NL, Stein H, Campo E, Pileri SA, Swerdlow SH. Introduction and overview of the classification of the lymphoid neoplasms. In: Swerdlow S, et al., editors. WHO classification of tumors of hematopoietic and lymphoid tissues. Lyon: International Agency For Research On Cancer; 2008. p. 158\u201366."},{"key":"1522_CR2","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1172\/JCI61205","volume":"122","author":"SA Pileri","year":"2012","unstructured":"Pileri SA, Piccaluga PP. New molecular insight into peripheral T cell lymphomas. J Clin Invest. 2012;122:3448\u201355.","journal-title":"J Clin Invest"},{"key":"1522_CR3","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1136\/jcp.2008.055335","volume":"61","author":"C Agostinelli","year":"2008","unstructured":"Agostinelli C, Piccaluga PP, Went P, Rossi M, Gazzola A, Righi S, et al. Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies. J Clin Pathol. 2008;61:1160\u20137.","journal-title":"J Clin Pathol"},{"key":"1522_CR4","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D. International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124\u201330.","journal-title":"J Clin Oncol"},{"key":"1522_CR5","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","volume":"111","author":"KJ Savage","year":"2008","unstructured":"Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, et al. International Peripheral T-Cell Lymphoma Project. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-cell Lymphoma Project. Blood. 2008;111:5496\u2013504.","journal-title":"Blood"},{"key":"1522_CR6","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1200\/JCO.2012.42.5611","volume":"31","author":"PP Piccaluga","year":"2013","unstructured":"Piccaluga PP, Fuligni F, De Leo A, Bertuzzi C, Rossi M, Bacci F, et al. Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. J Clin Oncol. 2013;31:3019\u201325.","journal-title":"J Clin Oncol"},{"key":"1522_CR7","doi-asserted-by":"crossref","first-page":"10703","DOI":"10.1158\/0008-5472.CAN-07-1708","volume":"67","author":"PP Piccaluga","year":"2007","unstructured":"Piccaluga PP, Agostinelli C, Califano A, Carbone A, Fantoni L, Ferrari S, et al. Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res. 2007;67:10703\u201310.","journal-title":"Cancer Res"},{"key":"1522_CR8","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1200\/JCO.2008.20.9759","volume":"28","author":"R Piva","year":"2010","unstructured":"Piva R, Agnelli L, Pellegrino E, Todoerti K, Grosso V, Tamagno I, et al. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. J Clin Oncol. 2010;28:1583\u201390.","journal-title":"J Clin Oncol"},{"key":"1522_CR9","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood-2009-06-227579","volume":"115","author":"J Iqbal","year":"2010","unstructured":"Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. International Peripheral T-Cell Lymphoma Project. Blood. 2010;115:1026\u201336.","journal-title":"Blood."},{"key":"1522_CR10","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","volume":"98","author":"E Sabattini","year":"2013","unstructured":"Sabattini E, Pizzi M, Tabanelli V, Baldin P, Sacchetti CS, Agostinelli C, et al. CD30 expression in peripheral T-cell lymphomas. Haematologica. 2013;98:e81\u20132.","journal-title":"Haematologica"},{"key":"1522_CR11","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/MOH.0b013e3283623c07","volume":"20","author":"F Tabb\u00f2","year":"2013","unstructured":"Tabb\u00f2 F, Ponzoni M, Rabadan R, Bertoni F, Inghirami G, European T-cell Lymphoma Study Group. Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma. Curr Opin Hematol. 2013;20:374\u201381.","journal-title":"Curr Opin Hematol"},{"key":"1522_CR12","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","volume":"120","author":"F Lemonnier","year":"2012","unstructured":"Lemonnier F, Couronn\u00e9 L, Parrens M, Ja\u00efs JP, Travert M, Lamant L, et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood. 2012;120:1466\u20139.","journal-title":"Blood"},{"key":"1522_CR13","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","volume":"119","author":"RA Cairns","year":"2012","unstructured":"Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais JP, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012;119:1901\u20133.","journal-title":"Blood"},{"key":"1522_CR14","doi-asserted-by":"crossref","unstructured":"Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N. A targeted mutational landscape of angioimmunoblastic T cell lymphoma. Blood. 2013 (Epub ahead of print).","DOI":"10.1182\/blood-2013-10-531509"},{"key":"1522_CR15","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood.V122.21.843.843","volume":"122","author":"JH Schatz","year":"2013","unstructured":"Schatz JH, et al. 55th ASH annual meeting and exposition. Blood. 2013;122:843.","journal-title":"Blood"},{"key":"1522_CR16","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3324\/haematol.2011.061507","volume":"97","author":"MH Delfau-Larue","year":"2012","unstructured":"Delfau-Larue MH, de Leval L, Joly B, Plonquet A, Challine D, Parrens M, Delmer A. Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. Haematologica. 2012;97:1594\u2013602.","journal-title":"Haematologica"},{"key":"1522_CR17","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","volume":"263","author":"SW Morris","year":"1994","unstructured":"Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s Lymphoma. Science. 1994;263:1281\u20134.","journal-title":"Science"},{"key":"1522_CR18","doi-asserted-by":"crossref","unstructured":"Inghirami G, Pileri SA, European T-Cell Lymphoma Study Group. Anaplastic large-cell lymphoma. Semin Diagn Pathol. 2011;28:190\u2013201 (Review).","DOI":"10.1053\/j.semdp.2011.03.002"},{"key":"1522_CR19","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1530\/JME-11-0004","volume":"47","author":"A Barreca","year":"2011","unstructured":"Barreca A, Lasorsa E, Riera L, Machiorlatti R, Piva R, Ponzoni M, European T-Cell Lymphoma Study Group, et al. Anaplastic-lymphoma kinase in human cancer. J Mol Endocrinol. 2011;47:R11\u201323.","journal-title":"J Mol Endocrinol"},{"key":"1522_CR20","unstructured":"Delsol G, Jaffe ES, Falini B, Gascoyne RD, Muller-Hermelink HK, Stein H, Campo, et al. Anaplastic large cell lymphoma (ALCL), ALK-positive. In: Swerdlow S et al., editors. WHO classification of tumors of hematopoietic and lymphoid tissues. Lyon, France: International Agency For Research On Cancer; 2008. p. 312\u201316."},{"key":"1522_CR21","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nm1249","volume":"11","author":"R Chiarle","year":"2005","unstructured":"Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med. 2005;11:623\u20139.","journal-title":"Nat Med"},{"key":"1522_CR22","doi-asserted-by":"crossref","unstructured":"Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008; 8:11\u201323 (Review).","DOI":"10.1038\/nrc2291"},{"key":"1522_CR23","doi-asserted-by":"crossref","unstructured":"Zamo\u2019 A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M, et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene. 2002; 21:1038\u201347.","DOI":"10.1038\/sj.onc.1205152"},{"key":"1522_CR24","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nm1769","volume":"14","author":"R Chiarle","year":"2008","unstructured":"Chiarle R, Martinengo C, Mastini C, Ambrogio C, D\u2019Escamard V, Forni G, et al. The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nat Med. 2008;14:676\u201380.","journal-title":"Nat Med"},{"key":"1522_CR25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2005-05-2125","volume":"107","author":"R Piva","year":"2006","unstructured":"Piva R, Chiarle R, Manazza AD, Taulli R, Simmons W, Ambrogio C, et al. Ablation of oncogenic Alk is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood. 2006;107:689\u201397.","journal-title":"Blood"},{"key":"1522_CR26","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","volume":"14","author":"YP Moss\u00e9","year":"2013","unstructured":"Moss\u00e9 YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children\u2019s Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14:472\u201380.","journal-title":"Lancet Oncol."},{"key":"1522_CR27","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMc1013224","volume":"364","author":"C Gambacorti-Passerini","year":"2011","unstructured":"Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med. 2011;364:775\u20136.","journal-title":"N Engl J Med"},{"key":"1522_CR28","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/sj.onc.1204128","volume":"20","author":"G Hubinger","year":"2001","unstructured":"Hubinger G, Muller E, Scheffrahn I, et al. CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1\/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299. Oncogene. 2001;20:590\u20138.","journal-title":"Oncogene"},{"key":"1522_CR29","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2353\/ajpath.2008.070858","volume":"172","author":"B Hirsch","year":"2008","unstructured":"Hirsch B, Hummel M, Bentink S, et al. CD30-induced signaling is absent in Hodgkin\u2019s cells but present in anaplastic large cell lymphoma cells. Am J Pathol. 2008;172:510\u201320.","journal-title":"Am J Pathol"},{"key":"1522_CR30","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1200\/JCO.2006.07.8972","volume":"25","author":"SM Ansell","year":"2007","unstructured":"Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R, Keler T, et al. Phase I\/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin\u2019s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol. 2007;25:2764\u20139.","journal-title":"J Clin Oncol"},{"key":"1522_CR31","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1182\/blood-2005-01-0427","volume":"106","author":"B Boll","year":"2005","unstructured":"Boll B, Hansen H, Heuck F, et al. The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis. Blood. 2005;106:1839\u201342.","journal-title":"Blood"},{"key":"1522_CR32","first-page":"5335","volume":"55","author":"ZG Tian","year":"1995","unstructured":"Tian ZG, Longo DL, Funakoshi S, et al. In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. Cancer Res. 1995;55:5335\u201341.","journal-title":"Cancer Res"},{"key":"1522_CR33","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2009.07740.x","volume":"146","author":"A Forero-Torres","year":"2009","unstructured":"Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146:171\u20139.","journal-title":"Br J Haematol"},{"key":"1522_CR34","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2011","unstructured":"Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2011;363:1812\u201321.","journal-title":"N Engl J Med"},{"key":"1522_CR35","first-page":"317","volume-title":"WHO classification of tumors of hematopoietic and lymphoid tissues","author":"DY Mason","year":"2008","unstructured":"Mason DY, Harris NL, Delsol G, Stein H, Campo E, Kinney MC, et al. Anaplastic large cell lymphoma (ALCL), ALK-negative. In: Swerdlow S, et al., editors. WHO classification of tumors of hematopoietic and lymphoid tissues. Lyon: International Agency For Research On Cancer; 2008. p. 317\u20139."},{"key":"1522_CR36","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2010-08-303305","volume":"117","author":"AL Feldman","year":"2011","unstructured":"Feldman AL, Dogan A, Smith DI, Law ME, Ansell SM, Johnson SH, et al. Discovery of recurrent t(6;7) (p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood. 2011;117:915\u20139.","journal-title":"Blood"},{"key":"1522_CR37","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/nm.2966","volume":"18","author":"D Laimer","year":"2012","unstructured":"Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O, et al. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med. 2012;18:1699\u2013704.","journal-title":"Nat Med"},{"key":"1522_CR38","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S0140-6736(74)90553-4","volume":"1","author":"G Frizzera","year":"1974","unstructured":"Frizzera G, Moran E, Rappaport H. Angio-immunoblastic lymphadenopathy with dysproteinemia. Lancet. 1974;1:1070\u20133.","journal-title":"Lancet"},{"key":"1522_CR39","first-page":"309","volume-title":"WHO classification of tumors of hematopoietic and lymphoid tissues","author":"A Dogan","year":"2008","unstructured":"Dogan A, Gaulard P, Jaffe E, Ralfkiaer E, Muller-Hermelink H, et al. Angioimmunoblastic T-cell lymphoma. In: Swerdlow S, et al., editors. WHO classification of tumors of hematopoietic and lymphoid tissues. Lyon: International Agency For Research On Cancer; 2008. p. 309\u201331."},{"key":"1522_CR40","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood.V82.1.241.bloodjournal821241","volume":"82","author":"LV Abruzzo","year":"1993","unstructured":"Abruzzo LV, Schmidt K, Weiss LM, et al. B-cell lymphoma after angioimmunoblastic lymphadenopathy: a case with oligoclonal gene rearrangements associated with Epstein-Barr virus. Blood. 1993;82:241\u20136.","journal-title":"Blood"},{"key":"1522_CR41","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0925-5710(98)00005-X","volume":"67","author":"K Matsue","year":"1998","unstructured":"Matsue K, Itoh M, Tsukuda K, Kokubo T, Hirose Y. Development of Epstein-Barr virus-associated B cell lymphoma after intensive treatment of patients with angioimmunoblastic lymphadenopathy with dysproteinemia. Int J Hematol. 1998;67:319\u201329.","journal-title":"Int J Hematol"},{"key":"1522_CR42","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1038\/sj.leu.2402642","volume":"16","author":"C Lome-Maldonado","year":"2002","unstructured":"Lome-Maldonado C, Canioni D, Hermine O, et al. Angio-immunoblastic T cell lymphoma (AILD-TL) rich in large B cells and associated with Epstein-Barr virus infection: a different subtype of AILD-TL? Leukemia. 2002;16:2134\u201341.","journal-title":"Leukemia"},{"key":"1522_CR43","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/01.pas.0000209855.28282.ce","volume":"30","author":"DM Dorfman","year":"2006","unstructured":"Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ. Programmed death-1 (PD-1) is a marker of germinal center associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2006;30:802\u201310.","journal-title":"Am J Surg Pathol"},{"key":"1522_CR44","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","volume":"24","author":"P Went","year":"2006","unstructured":"Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24:2472\u20139.","journal-title":"J Clin Oncol"},{"key":"1522_CR45","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/blood-2006-01-0394","volume":"108","author":"L Krenacs","year":"2006","unstructured":"Krenacs L, Schaerli P, Kis G, Bagdi E. Phenotype of neoplastic cells in angioimmunoblastic T-cell lymphoma is consistent with activated follicular B helper T cells. Blood. 2006;108:1110\u20131.","journal-title":"Blood"},{"key":"1522_CR46","doi-asserted-by":"crossref","unstructured":"Roncador G, Garcia Verdes-Montenegro JF, Tedoldi S, Paterson JC, Klapper W, Ballabio E, et al. Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. Haematologica. 2007;92:1059\u201366.","DOI":"10.3324\/haematol.10864"},{"key":"1522_CR47","doi-asserted-by":"crossref","unstructured":"de Leval L, Rickman DS, Thielen C, Reynies Ad, Huang YL, Delsol G, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T cells (TFH). Blood. 2007;109:4952\u201363.","DOI":"10.1182\/blood-2006-10-055145"},{"key":"1522_CR48","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1056\/NEJMra0707449","volume":"361","author":"P Miossec","year":"2009","unstructured":"Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361:888\u201398.","journal-title":"N Engl J Med"},{"key":"1522_CR49","doi-asserted-by":"crossref","first-page":"792","DOI":"10.2353\/ajpath.2010.091286","volume":"177","author":"C Tripodo","year":"2010","unstructured":"Tripodo C, Gri G, Piccaluga PP, Frossi B, Guarnotta C, Piconese S, Franco G, et al. Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma. Am J Pathol. 2010;177:792\u2013802.","journal-title":"Am J Pathol"},{"key":"1522_CR50","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1038\/labinvest.3700145","volume":"84","author":"WL Zhao","year":"2004","unstructured":"Zhao WL, Mourah S, Mounier N, Leboeuf C, Daneshpouy ME, Legr\u00e8s L, et al. Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab Invest. 2004;84:1512\u20139.","journal-title":"Lab Invest"},{"key":"1522_CR51","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1038\/sj.leu.2403936","volume":"19","author":"I Bruns","year":"2005","unstructured":"Bruns I, Fox F, Reinecke P, Kobbe G, Kronenwett R, Jung G, Haas R. Complete remission in a patient withrelapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia. 2005;19:1993\u20135.","journal-title":"Leukemia"},{"key":"1522_CR52","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/10428190210190","volume":"43","author":"C Strupp","year":"2002","unstructured":"Strupp C, Aivado M, Germing U, Gattermann N, Haas R. Angioimmunoblastic lymphadenopathy (AILD) mayrespond to thalidomide treatment: two case reports. Leuk Lymphoma. 2002;43:133\u20137.","journal-title":"Leuk Lymphoma."},{"key":"1522_CR53","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/sj.leu.2403710","volume":"19","author":"A Dogan","year":"2005","unstructured":"Dogan A, Ngu LS, Ng SH, Cervi PL. Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide. Leukemia. 2005;19:873\u20135.","journal-title":"Leukemia."},{"key":"1522_CR54","doi-asserted-by":"crossref","unstructured":"Dueck GS, Chua N, Prasad A, Stewart D, White D, van der Jagt R, et al. Activity of lenalidamide in a phase II trial for T-cell lymphoma: report on the first 24 cases. J Clin Oncol. 2009; 27:439s (suppl; abstr 8524).","DOI":"10.1200\/jco.2009.27.15_suppl.8524"},{"key":"1522_CR55","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood.V122.21.815.815","volume":"122","author":"M Sakata-Yanagimoto","year":"2013","unstructured":"Sakata-Yanagimoto M, et al. 55th ASH annual meeting and exposition. Blood. 2013;122:815.","journal-title":"Blood"},{"key":"1522_CR56","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood.V122.21.846.846","volume":"122","author":"T Palomero","year":"2013","unstructured":"Palomero T, et al. 55th ASH annual meeting and exposition. Blood. 2013;122:846.","journal-title":"Blood"},{"key":"1522_CR57","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1365-2141.2009.07956.x","volume":"148","author":"S Hartmann","year":"2010","unstructured":"Hartmann S, Gesk S, Scholtysik R, Kreuz M, Bug S, Vater I, et al. High resolution SNP array genomic profiling of peripheral T cell lymphomas, not otherwise specified, identifies a subgroup with chromosomal aberrations affecting the REL locus. Br J Haematol. 2010;148:402\u201312.","journal-title":"Br J Haematol"},{"key":"1522_CR58","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2141.2008.07042.x","volume":"141","author":"M Nelson","year":"2008","unstructured":"Nelson M, Horsman DE, Weisenburger DD, Gascoyne RD, Dave BJ, Loberiza FR. Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma. Br J Haematol. 2008;141:461\u20139.","journal-title":"Br J Haematol."},{"key":"1522_CR59","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-08-1808","volume":"15","author":"M Nakagawa","year":"2009","unstructured":"Nakagawa M, Nakagawa-Oshiro A, Karnan S, Tagawa H, Utsunomiya A, Nakamura S. Array comparative genomic hybridization analysis of PTCL-U reveals a distinct subgroup with genetic alterations similar to lymphoma-type adult T-cell leukemia\/lymphoma. Clin Cancer Res. 2009;15:30\u20138.","journal-title":"Clin Cancer Res"},{"key":"1522_CR60","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hon.781","volume":"24","author":"B Martinez-Delgado","year":"2006","unstructured":"Martinez-Delgado B. Peripheral T-cell lymphoma gene expression profiles. Hematol Oncol. 2006;24:113\u20139.","journal-title":"Hematol Oncol"},{"key":"1522_CR61","doi-asserted-by":"crossref","unstructured":"Martinez-Delgado B, Cuadros M, Honrado E, Ruiz de la Parte A, Roncador G, Alves J, et al. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia. 2005;19:2254\u201363.","DOI":"10.1038\/sj.leu.2403960"},{"key":"1522_CR62","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/sj.onc.1209178","volume":"25","author":"B Ballester","year":"2006","unstructured":"Ballester B, Ramuz O, Gisselbrecht C, Doucet G, Loi L, Loriod B, et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene. 2006;25:1560\u201370.","journal-title":"Oncogene"},{"key":"1522_CR63","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1200\/JCO.2006.09.4474","volume":"25","author":"M Cuadros","year":"2007","unstructured":"Cuadros M, Dave SS, Jaffe ES, Honrado E, Milne R, Alves J, et al. Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. J Clin Oncol. 2007;25:3321\u20139.","journal-title":"J Clin Oncol"},{"key":"1522_CR64","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.leu.2404045","volume":"20","author":"B Streubel","year":"2006","unstructured":"Streubel B, Vinatzer U, Willheim M, Chott A. Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia. 2006;20:313\u20138.","journal-title":"Leukemia"},{"key":"1522_CR65","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/PAS.0b013e3181971591","volume":"33","author":"Y Huang","year":"2009","unstructured":"Huang Y, Moreau A, Dupuis J, Streubel B, Petit B, Le Gouill S, et al. Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas. Am J Surg Pathol. 2009;33:682\u201390.","journal-title":"Am J Surg Pathol"},{"key":"1522_CR66","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/leu.2012.304","volume":"27","author":"SD Turner","year":"2013","unstructured":"Turner SD. Inimitable Imatinib: the range of targeted tumours expands to include T-cell lymphoma. Leukemia. 2013;27:759.","journal-title":"Leukemia"},{"key":"1522_CR67","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince M, et al. Final results from a pivotal, multicenter, international open-label, phase 2 study of Romidepsin in progressive or relapsed peripheral T-cell lymphoma (PTCL) following prior systemic therapy. J Clin Oncol. 2012;30:631\u20136.","journal-title":"J Clin Oncol"},{"key":"1522_CR68","doi-asserted-by":"crossref","unstructured":"Mahadevan D, Spier C, Della Croce K, Miller S, George B, Riley C, et al. Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures. Mol Cancer Ther. 2005;4:1867\u201379.","DOI":"10.1158\/1535-7163.MCT-05-0146"},{"key":"1522_CR69","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/leu.2010.255","volume":"25","author":"J Iqbal","year":"2011","unstructured":"Iqbal J, Weisenburger DD, Chowdhury A, Tsai MY, Srivastava G, Greiner TC, et al. Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gamma\/delta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro. Leukemia. 2011;25:348\u201358.","journal-title":"Leukemia"},{"key":"1522_CR70","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.leukres.2012.10.017","volume":"37","author":"W Qia","year":"2013","unstructured":"Qia W, Spiera C, Liua X, Agarwala A, Cookea LS, Perskyb DO, et al. Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leuk Res. 2013;37:434\u20139.","journal-title":"Leuk Res"},{"key":"1522_CR71","doi-asserted-by":"crossref","unstructured":"Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, et al. Phase II study of Alisertib, a selective Aurora-Kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2013 (Epub ahead of print).","DOI":"10.1200\/JCO.2012.46.8793"},{"key":"1522_CR72","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V122.21.811.811","volume":"122","author":"AA Ferrando","year":"2013","unstructured":"Ferrando AA, et al. 55th ASH annual meeting and exposition. Blood. 2013;122:811.","journal-title":"Blood"},{"issue":"4","key":"1522_CR73","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1586\/ehm.11.37","volume":"4","author":"PP Piccaluga","year":"2011","unstructured":"Piccaluga PP, Agostinelli C, Tripodo C, Gazzola A, Bacci F, Sabattini E, Pileri SA. Peripheral T-cell lymphoma classification: the matter of cellular derivation. Expert Rev Hematol. 2011;4(4):415\u201325.","journal-title":"Expert Rev Hematol."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-014-1522-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-014-1522-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-014-1522-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T04:08:27Z","timestamp":1688962107000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-014-1522-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,31]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["1522"],"URL":"https:\/\/doi.org\/10.1007\/s12185-014-1522-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,31]]}}}